| Name | Title | Contact Details |
|---|
TriCore Reference Laboratories is a community-based, independent, clinical reference laboratory that provides full-service, state-of-the-art laboratory tests to health care professionals and their patients. Based in Albuquerque, N.M., with clients in New Mexico and across the US. TriCore offers more than 1,500 laboratory tests ranging from routine (such as cholesterol screens) to highly specialized (such as genetic testing). TriCore participates in scientific research through collaboration with the University of New Mexico and numerous national and international biotech firms.
Maryland Health Benefit Exchange’s (MHBE) resource site for stakeholders. We continue to work toward the opening of the marketplace in October 2013 of Maryland Health Connection, the state-based health insurance exchange where Maryland residents and small businesses will be able to explore and compare health insurance plans, qualify for cost-sharing reductions and tax credits and complete the enrollment process. The information available through this site supports our work with stakeholders. Meeting schedules and materials, career information, and procurement details are routinely posted. Additionally, the site serves as a resource for the many advisory committees and programs in progress and in development as we collectively work together to establish a health insurance marketplace that best meets the needs of all Marylanders.
Xymogen is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FORBA is a Pueblo, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.